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Abstract
Introduction: Degradation in fractal motor activity regulation (FMAR), a measure of
multiscale self-similarity of motor control, occurs in aging and accelerates with clinical progression to Alzheimer’s disease (AD). Whether FMAR changes occur during the
pre-symptomatic phase of the disease in women and men remains unknown.
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Methods: FMAR was assessed in cognitively normal participants (n = 178) who
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underwent 7 to 14 days of home actigraphy. Preclinical AD pathology was deter-
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mined by amyloid imaging-Pittsburgh compound B (PiB) and cerebrospinal fluid (CSF)
phosphorylated-tau181 (p-tau) to amyloid beta 42 (Aβ42) ratio.
Results: Degradation in daytime FMAR was overall significantly associated with preclinical amyloid plaque pathology via PiB+ imaging (beta coefficient β = 0.217, standard error [SE] = 0.101, P = .034) and increasing CSF tau181-Aβ42 ratio (β = 0.220,
SE = 0.084, P = .009). In subset analysis by sex, the effect sizes were significant in
women for PiB+ (β = 0.279, SE = 0.112, P = .015) and CSF (β = 0.245, SE = 0.094,
P = .011) but not in men (both Ps > .05). These associations remained after inclusion of
daily activity level, apolipoprotein E ε4 carrier status, and rest/activity patterns.
Discussion: Changes in daytime FMAR from actigraphy appear to be present in women
early in preclinical AD. This may be a combination of earlier pathology changes
in females reflected in daytime FMAR, and a relatively underpowered male group.
Further studies are warranted to test FMAR as an early noncognitive physiological
biomarker that precedes the onset of cognitive symptoms.
KEYWORDS

actigraphy, amyloid positron emission tomography imaging, amyloid plaque pathology, amyloid
beta 42, fractal regulation, interdaily stability, intradaily variability, phosphorylated tau, Pittsburgh compound B, preclinical Alzheimer’s disease, sex differences
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INTRODUCTION

the role of continuous monitoring of motor activity in free-living adults
in predicting cognitive decline.2,3 Recently, it was shown that the

Alzheimer’s disease (AD) continues to lack early and readily obtained

self-similarity of actigraphy-derived motor activity fluctuations when

biomarkers of risk in earlier life.1 There has been increasing interest in

magnified across different time scales, known as fractal motor activity
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regulation (FMAR), is linked to AD; and alterations in FMAR coincided
with cognitive decline, accelerating during progression to mild cogni-

RESEARCH IN CONTEXT

tive impairment (MCI), through mild/moderate/severe dementia.4–6

1. Systematic review: Recent studies indicate that frac-

In fact, complex temporal patterns including fractal patterns
have been observed in many physiological signals7–9 such as gait,10

tal motor activity regulation (FMAR) may be a novel

mobility,11 motor function,12 and activity patterns,4,5 all of which have

biomarker for Alzheimer’s disease (AD), particularly in

been linked to AD and pathology.13–16 It has been accepted that fractal

elderly subjects during the years prior to diagnosis. However, the relationship between FMAR degradation and

patterns are generated by multiple such processes in an ongoing
feedback loop.7

preclinical AD pathology in younger, cognitively normal

In addition to AD diagnosis, perturbed daytime FMAR

adults is unknown.

has been associated with increased disability, frailty, and mortality in

2. Interpretation: This study showed for the first time a

the elderly.3,15,17,18 However, much of this evidence has either been
close to AD

diagnosis3,19

or

thereafter.6

link between FMAR and AD via preclinical pathology in

The relationship between

women that was independent of age, race, education,

daytime FMAR and early, preclinical AD pathology in cognitively

daily activity, and apolipoprotein E ε4 status.

normal individuals is unknown.

3. Future directions: Future studies may aim to (1) repli-

In this study, we analyzed the relationship between daytime FMAR

cate the associations between FMAR and preclinical AD

and both imaging and cerebrospinal fluid (CSF)-derived amyloid and

pathology in larger samples of men; (2) determine what

tau AD biomarkers in cognitively normal participants who underwent

mechanisms underlie these associations; (3) test the rela-

7 to 14 days of actigraphy in their home environment. We accounted

tionship between FMAR alterations and other types of

for apolipoprotein E (APOE) ε4 carrier status and examined potential

dementia; and (4) explore whether interventions can

sex differences in FMAR given prior evidence for links between sex

modulate FMAR as a way to delay the onset of AD.

and AD pathology.20

2

METHODS
HIGHLIGHTS

2.1

Subjects

1. Fractal motor activity regulation (FMAR) is associated
with preclinical Alzheimer’s disease (AD) pathology in

All participants were from the Washington University Knight

cognitively normal women.

Alzheimer’s Disease Research Center (ADRC) in St. Louis, Missouri.

2. The relationship is independent of age, physical activity,

Inclusion criteria were age over 45 years, no cognitive impairment

rest-activity pattern fragmentation, and apolipoprotein E

(Clinical Dementia Rating score 0), and no abnormal movement of the

ε4 carrier status.

nondominant arm. Participants provided written, informed consent

3. FMAR may represent a novel biomarker for preclinical AD

for an add-on actigraphy study, described in detail elsewhere.16,21

pathology.

We included 178 participants (mean age [standard deviation (SD)]
65.9 [8.3] years) who completed the actigraphy study, and had at
least one AD biomarker available through the ADRC. Participant
procedures were approved by the Washington University Human

tau181 (p-tau) were measured by the ADRC Biomarker Core using

Research Protection Office. This current analysis was approved by

enzyme-linked immunosorbent assay (INNOTEST; Innogenetics).16

the Partners Healthcare, Inc. Institutional Review Board and was part

CSF p-tau—to–Aβ42 ratio was calculated as a sensitive and specific

of the Knight ADRC-approved project D1821 (Neuropathology for

biomarker for AD-related neurodegeneration given its specificity for

disrupted multiscale activity control in Alzheimer’s disease).

preclinical AD, and conversion to symptomatic AD.24 Consistent with
a recent study, all participants had biomarker data from 3 years before
to 0.5 years after actigraphy recording included in this study, and irre-

2.2

Biomarkers of AD pathology

versibility of AD pathology was assumed.16 In summary, biomarkers of
preclinical AD pathology used in this study were (1) PiB status (PiB+ or

Pittsburgh compound B (PiB) positron emission tomography (PET)

PiB–) as a dichotomous variable, and (2) p-tau–to–Aβ42 ratio as a con-

amyloid imaging was performed in 150 and cerebrospinal fluid (CSF)

tinuous variable.

was obtained in 149 participants (121 participants had both, whereas
57 had one AD biomarker only). An a priori cut-off value of total mean
cortical standard-uptake-value ratio > 1.42 as PiB positive (PiB+),

2.3

Data collection and preprocessing

using the regional spread function technique; those ≤ 1.42 were
deemed PiB negative (PiB–).22 CSF was obtained via lumbar puncture

Motor activity was continuously monitored for 14 days using an acti-

as previously described.23

graph monitor (Actiwatch2; Phillips-Respironics) worn on the non-

Amyloid beta 42 (Aβ42) and phosphorylated
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F I G U R E 1 Fractal motor activity regulation measurement. Representative motor activity recordings from actigraphy over one full
representative week for two participants, with Δα values in the 90th (A: in red) and 10th percentiles (B: in black) are shown. Gray shading indicates
7 PM to 11 AM data, which were excluded. C, F(n) is fitted using a power law, indicating a fractal structure in the fluctuations, and is plotted against
time on a log-log scale. F(n) is fitted separately in two regions: 1.25 to 90 minutes, and 120 to 600 minutes. The slopes of the lines in the two
regions are α1 and α2 , respectively. Δα is the difference between the two slopes, α1 and α2 ; higher Δα is worse, indicating an inconsistency of fractal
motor activity regulation between the shorter and longer time scales

dominant wrist. Data were sampled at 32 Hz and integrated into 30-

physiological outputs under healthy conditions have a value close to

second epochs. To ensure good signal quality, recordings were checked

1.0.28 This imitates the behavior of “pink” (1/f) noise, a signal/process

using an established MATLAB GUI program (Ver. R2015a, the Math-

in which the power spectral density is inversely proportional to the sig-

15,25,26

and quality issues such as (1) isolated spikes with

nal frequency; it represents a delicate balance between total random-

amplitude beyond 10 SD away from the individual global mean levels;

ness (white noise) with no control and excessive regularity (periodic

and (2) sequences of zeros with duration > 60 minutes during the day-

signals), with too rigid a control (no response or flexibility). In fact, this

time (likely representing off-wrist periods) were identified and marked

is one of the most common patterns in the output of healthy biological

as gaps.27,28

systems,30 including the brain activity; recent evidence suggests that

Works Inc.)

Finally, each recording was manually inspected to confirm

quality control prior to FMAR assessment.

pink noise can enhance slow-wave sleep (associated with memory consolidation) in patients with MCI.31
FMAR degradation can be assessed from the changes in F(n) and α.

2.4

One typical change is decreases in α values with age (i.e., motor activity

Fractal motor activity regulation

fluctuations become more like white noise).3,7,32 However, the rate of
To assess FMAR, we investigated the temporal correlation property

decrease appears to be disproportionate over two time scale regions

of motor activity fluctuation at an array of timescales by perform-

in AD and dementia with faster decline at time scales > 2 hours (up to

ing detrended fluctuation analysis (DFA) with two-order polynomial

24 hours, α2 ) than < 90 minutes (α1 ); this leads to the deviation of F(n)

detrending.28,29 The DFA calculates the fluctuation amplitude, F(n), as

from a power-law form (a straight line) with α1 > α2 .4–6,32 Therefore,

F(n)∼nα ,

we used the difference, that is, Δα = α1 -α2 , to assess such degradation

indicates a fractal structure in the fluctuations (Figure 1). The temporal

in FMAR (Figure 1). Increased Δα was previously observed to be more

correlation in the fluctuations can be quantified by the scaling expo-

strongly linked with neurodegeneration,32 particularly in the suprachi-

nent, α, where 0.5 indicates no correlation in the fluctuations (“white

asmatic nucleus, and with cortical amyloid plaque burden, versus core

noise”), and > 0.5 indicates positive, whereas < 0.5 indicates negative

body temperature and motor activity derived rest/activity measures.33

temporal correlations. Positive temporal correlation implies that adja-

In addition, we focused on peak daytime activity data (i.e., 11 AM-7 PM)

cent values in time tend to have similar values (i.e., large values more

to assess FMAR changes independent of the potential effects of altered

likely followed by large values), and negative temporal correlation sug-

sleep that may cause nocturnal motor activity. Collectively, considering

gests that adjacent values in time are more likely different from each

an epoch length of 30 seconds and the decreased length of consecu-

other (i.e., large values more likely followed by small values). Mathe-

tive data recordings due to the exclusion of nighttime period/gaps, we

matically, the upper limit for α is 3 for the DFA using two-order poly-

quantified α1 in the range of 3 to 90 minutes and α2 in the range of 2 to

nomial detrending (stronger correlations for larger values),27

8 hours.

a function of time scale n. A power-law form of F(n), that is,

but most
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TA B L E 1

Participant characteristics

Characteristic

All (n = 178)

PiB+

PiB–

Mean (SD) or N (%)

(n = 33)

(n = 117)

P

Age, years

65.9 (8.3)

69.8 (5.4)

64.6 (8.6)

.001

Sex, women

117 (66%)

20 (61%)

80 (68%)

.44

Education, years

16.2 (2.4)

15.6 (2.5)

16.3 (2.4)

.14

Race, non-Hispanic white

167 (94%)

32 (97%)

110 (94%)

.68

APOE ε4 carrier

66 (37%)

18 (55%)

38 (32%)

.02

log(p-tau–to–Aβ42)*

NA

–0.89 (0.26)

–1.21 (0.18)

<.001

Abbreviations: Aβ, amyloid beta; APOE, apolipoprotein E; PiB, Pittsburgh compound B; SD, standard deviation.
Notes: APOE ε4 carrier (1 or 2 alleles); log(pTau-to-Aβ42) cerebrospinal fluid phosphorylated Tau 181 (pTau) to amyloid-β-42 (Aβ42) ratio, log transformed for
non-normal distribution.
*121 participants with both PIB and log(pTau-to-Ab42) available.

2.5

Assessment of covariates

were explored, but were not significant. Therefore, the time lag was
not included as a covariate to preserve degrees of freedom. Related to

Age was in years at start of actigraphy recording. Biological sex at birth,

this, to assess clinical utility of FMAR (alongside age, sex, race, educa-

race (non-Hispanic White, Black, or other), education (years) were self-

tion, daily activity, and APOE) in the prediction of AD biomarker sta-

reported. APOE ε4 genotype was dichotomized to carrier (one or two

tus, we also included further analysis examining the odds of prior PiB+

alleles) versus noncarrier. Mean daily activity was estimated from the

at the time of imaging, based on the upper half (≥ median) and lower

extent of actigraphy accelerations in arbitrary units (a.u.). We also con-

half (< median) of Δα, assuming that AD pathology was irreversible. All

sidered the following measures of rest/activity patterns using pub-

tests were two-sided, with an α level of 0.05. Statistical analyses were

lished results and methodology from this

cohort:16,34,35

(1) interdaily

performed using JMP Pro (Ver. 14, SAS Institute).

stability (IS) of daily activity rhythm (similarity between days; higher
values indicate more day-to-day stability);36 and (2) intradaily variability (IV; how consolidated the rest/activity rhythms are). Low IV results

3

RESULTS

occur when there is a continuous period of high activity and a continuous period of minimal activity during each day; higher IV indicates more

3.1

Participant characteristics

fragmentation of the rest/activity pattern.35
Demographics and characteristics of participants are summarized in
Table 1. Overall, the participants were more likely to be female (66%,

2.6

Statistical analysis

n = 117), aged (mean [SD]) 65.9 [8.3] years, and have had 16.2 [2.4]
years of education (Table 1). Among the 150 participants with PiB

We examined all continuous variables for normal distribution by visual

PET imaging, 22% (n = 33) were PiB+ and, compared to PiB– partici-

inspection of histograms and the Kolmogorov-Smirnov test. The p-

pants, they were older (69.8 [5.4] vs. 64.6 [8.6] years, P = .001), more

tau–to–Aβ42 ratio was log-transformed due to non-normal distribu-

often APOE ε4 carriers (55% vs. 32%, P = 0.02), and with higher log(p-

tion. Comparisons between two groups (PiB+ and PiB– status) were

tau/Aβ42) (–0.89 [0.26] vs. –1.21 [0.18], P < .001), in a subset of 121

conducted using independent t tests for normally distributed contin-

with both markers available. Figure 1 shows motor activity recordings

uous variables, Mann-Whitney U tests if non-normally distributed, or

over 1 week, and the corresponding FMAR (Δα) from two representa-

Chi-squared tests for categorical variables. Correlations were assessed

tive female participants at the same age (78 years), one PiB+ with Δα

with Pearson’s correlation.

in the 90th centile of the cohort, and one PiB– with Δα in the 10th cen-

We constructed multiple regression models with PiB status as a
dichotomous predictor, and separately with log (p-tau/Aβ42) as a con-

tile. FMAR was normally distributed, with a median value of 0.10, and
ranged from –0.45 to +0.48 (Figure 2).

tinuous predictor, accounting for available covariates that may affect

The effects of age, sex, daily activity level, and APOE ε4 genotype

both FMAR and preclinical AD pathology; these were entered step-

on daytime FMAR are shown in Figure 3. With increasing age, there

wise in the following order: our core model (Model A) included demo-

was a trend toward increased Δα but this effect was not significant

graphics (age, sex, education years, and ethnicity), Model B addition-

(r = 0.11, P = .13; Figure 3A). After adjusting for age, women had higher

ally included mean daily activity level, Model C added APOE ε4 geno-

Δα (0.10 vs. 0.04 in men, P = .016; Figure 3B). Daily activity level had

type, and Models D1 and D2 added two rest/activity measures one at a

no significant effect on Δα (r = –0.08, P = .25; Figure 3C). There was no

time given their known collinearity. The effects of the time lag between

significant difference in Δα between APOE ε4 carriers and non-carriers

AD biomarker assessment and FMAR assessment on all associations

(0.076 present vs. 0.074 absent, P = .88; Figure 3D).
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(Model B: estimate = 0.228, SE = 0.083, P = .007) and APOE genotype (Model C: estimate = 0.218, SE = 0.087, P = .013). Similarly, the
inclusion of IS/IV in Models D1-D2 did not affect the association. Full
model results for PiB status and log(p-tau/Aβ42) on Δα are summarized
in Tables S2-S3 in supporting information.
Given that we observed significantly higher Δα in women, a subset analysis by sex was performed (Table 2). The associations of Δα
with AD pathology measures were significant in women for both PiB+
(β = 0.279, SE = 0.112, P = .015) and CSF log(p-tau/Aβ42) (β = 0.245,
SE = 0.094, P = .011), but not in men for either PiB+ (β = 0.187,
SE = 0.201, P = .357) or CSF log(p-tau/Aβ42) (β = 0.130, SE = 0.167,
P = .438).

4

DISCUSSION

This study identified for the first time an association between FMAR
and preclinical AD biomarkers that warrants further investigation and
validation. We found that changes in daytime FMAR (higher Δα) were
F I G U R E 2 The distribution of the fractal motor activity regulation
Δα metric. The median value of 0.10 is represented by the black dotted
line. Red line represents 10th centile whereas the blue dotted line
represents the 90th centile

associated with preclinical AD pathology in healthy, cognitively normal adults, as measured by amyloid imaging (PiB status) or CSF ptau–to–Aβ42 ratio. These associations were significant after inclusion
of age, sex, education, race, mean daily activity, and APOE ε4 carrier
status. However, women had higher daytime FMAR degradation, and
appeared to drive the above associations. These findings suggest that

3.2

AD biomarkers and FMAR (Δα)

daytime FMAR imparts new information, particularly in women, about
AD pathogenesis at the early stage of the disease prior to the onset of

We compared PiB+ participants (n = 33) to PiB– participants (n = 119)

cognitive symptoms.

to examine the effect of amyloid plaque pathology on FMAR. PiB+ par-

Fractal regulation has been used to characterize health status and

ticipants had significantly higher daytime Δα than PiB– participants in

clinical outcome in many diseases,7 including the prediction of MCI

our core multivariate model after accounting for the potential effects

and AD dementia.4–6 We recently showed for the first time that FMAR

of age, sex, education, and race (Figure 3E). The magnitude of this dif-

predicted incident clinical AD by 5 years on average.3 However, given

ference in Δα was 21.7% of the SD when “All” subjects were included

that preclinical AD pathology may develop more than 10 to 20 years

(Table 2, Model A: estimate = 0.217, standard error [SE] = 0.101,

prior to symptomatic cognitive impairment,37,38 this is the first study

P = .034). This relationship remained unchanged after including mean

demonstrating an association between early preclinical AD pathology

daily activity level (Model B: estimate = 0.226, SE = 0.102, P = .028),

and FMAR changes. Additionally, Δα significantly associated with CSF

and APOE ε4 genotype (Model C: estimate = 0.223, SE = 0.105,

p-tau–to–Aβ42 ratio, a continuous measure of AD-specific pathology,

P = .035). After inclusion of individual rest/activity measures (IS and

suggesting that FMAR may be able to serve as a marker of preclinical

IV), the associations between PiB status and FMAR remained signifi-

AD progression.

cant (Models D1-D2; Table 2). In further analysis, when a participant

Interestingly, FMAR appeared to be more degraded in women than

had an assessed Δα in the upper half (≥0.10, median value in Figure 2),

men (P = .016, Figure 3B). This is in keeping with a prior study in healthy

there was significantly increased odds for prior PiB+ at the time of

subjects in which FMAR degradation appeared steeper in females,

imaging, compared to those in the lower half (odds ratio [OR] 3.32, 95%

starting as early as young adulthood between 30 and 40 years of

confidence interval [CI] 1.33–8.30, P = .010); this was independent of

age.39 However, in an elderly community cohort (also predominantly

age, sex, education, race, daily activity, and APOE (see Table S1 in sup-

women, but ≈20 years older than our cohort on average), FMAR degra-

porting information).

dation was higher with age, but no difference in FMAR degradation

We also examined CSF log(p-tau/Aβ42) as a continuous measure

was observed between sexes.3,6 In this study, FMAR degradation also

of AD-specific pathological burden. There was a positive correlation

trended higher with age, but was not significant. Thus, FMAR’s link to

between log(p-tau/Aβ42) and daytime Δα for all participants with

sex may well be age dependent. Δα, as one of many accepted FMAR

available CSF biomarkers (Figure 3F). In our core model, every 1-SD

measures, may only reflect an aspect of FMAR change that is influenced

increase in log(p-tau/Aβ42) was associated with a 22.0% SD increase

by sex, but only in younger cohorts.

in Δα (Table 2, Model A: estimate = 0.220, SE = 0.084, P = .009). This

Most importantly, though results were significant for the whole

relationship also remained unchanged after inclusion of daily activity

cohort, the associations between AD pathology and FMAR remained
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F I G U R E 3 Effect of Alzheimer’s disease (AD) biomarkers and demographic characteristics on fractal motor activity regulation. All plots show
Δα on the y axis, with higher values indicating more degradation of fractal motor activity regulation. A, Increasing age in years (y) was
non-significantly associated with higher Δα. B, Women had higher Δα. C, Decreased mean daily activity (in arbitrary units) was non-significantly
associated with higher Δα. Scatterplot shows linear regression line plus 95% confidence interval. D, There was no difference in Δα between APOE
ε4 carriers and non-carriers. E, Women with preclinical AD pathology, as defined by Pittsburgh compound B (PiB) positron emission tomography
(PET) positivity (PiB+), had higher Δα than participants who were PiB negative (PiB–). F, Greater AD-specific pathological burden, as measured by
cerebrospinal fluid phosphorylated tau 181 (p-tau) to amyloid beta 42 (Aβ42) ratio [log (p-tau/Aβ42)], was significantly correlated with higher Δα
in women (orange triangles and solid line; r = 0.26, P = .011), but not in men (blue circles and dashed line; r = 0.10, P = .438). Box plots show
interquartile range (IQR) as boxes, median as center line, and 1.5 x IQR as whiskers. Outliers are represented as individual markers. P values
adjusted for age (B) or age, sex, education, and race (C-F)

significant only in females. The effect sizes for PiB+ on FMAR appeared

(0.10 vs. 0.04 in men, P = .016). The possibility for earlier AD pathol-

larger in women, but in formal testing, being female did not significantly

ogy changes in women is supported by the other findings showing that

augment the effects of amyloid plaque positivity on FMAR degradation

women have higher prevalence of AD,40 faster cognitive decline41 and

(data not shown). The makeup of the Washington University ADRC, in

differences in underlying AD pathology, on both neuroimaging42 and

which the female sample size was larger than the male sample (66%

CSF.43 Taken together, this warrants further work within larger sam-

women, Table 1), resulted in lower standard errors (narrower con-

ples to examine FMAR changes during middle age,1 as well as the tra-

fidence intervals) for women, and/or greater variability in men (Fig-

jectory of FMAR with aging in both women and men using longitudinal

ure 3B), which may contribute to the sex differences for significance

within-subject study designs.

thresholds being reached in our fully adjusted models. However, power

Mechanistically, poor or impaired motor function, and low phys-

differences may not fully explain the significantly higher Δα in women

ical activity levels have all been linked to MCI, AD, and cognitive
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TA B L E 2

Sex-specific preclinical AD amyloid plaque pathology and disease burden on fractal motor activity regulation
PiB+/PiB–

log(p-tau/Aβ42)

β, SE

All

Female

Male

All

Female

Male

P value

n = 150

n = 100

n = 50

n = 149

n = 93

n = 56

Model A

0.217, 0.101

0.279, 0.112

0.187, 0.201

0.220, 0.084

0.245, 0.094

0.130, 0.167

(core)

0.034

0.015

0.357

0.009

0.011

0.438

Model B

0.226, 0.102

0.280, 0.112

0.199, 0.207

0.228, 0.083

0.231, 0.094

0.236, 0.176

(+daily activity)

0.028

0.014

0.341

0.007

0.017

0.187

Model C

0.223, 0.105

0.272, 0.115

0.215, 0.217

0.218, 0.087

0.224, 0.100

0.240, 0.188

(+APOE ε4)

0.035

0.020

0.327

0.013

0.026

0.209

Model D1

0.225, 0.106

0.267, 0.116

0.197, 0.221

0.224, 0.089

0.224, 0.089

0.201, 0.105

(+IS)

0.036

0.024

0.378

0.013

0.013

0.309

Model D2

0.214, 0.106

0.287, 0.118

0.204, 0.214

0.201, 0.092

0.279, 0.106

0.208, 0.200

(+IV)

0.044

0.017

0.347

0.030

0.010

0.594

Notes: Effects of amyloid plaque pathology (PiB, Pittsburgh compound B status) and cerebrospinal fluid (CSF) AD-specific disease burden biomarker log(ptau/Aβ42) on fractal motor activity regulation (FMAR) in all subjects, and by sex. β represents change in Δα in standard deviations (SDs), alongside corresponding standard errors (SE) and P values, for PiB+ compared to PiB–, or per each SD increase in log(p-tau/Aβ42). The core Model A included age, sex,
education, and ethnicity. Model B additionally included mean physical activity level. Model C additionally included APOE ε4 status. Models D1 and D2 additionally included for rest/activity measures IS interdaily stability, and IV intradaily variability.

decline.2,13,14,46,47 The current study showed a strong and consistent

Among the strengths of this study, to the best of our knowledge,

association between preclinical AD pathology and FMAR, raising the

these are the first results incorporating fractal regulation and in vivo

possibility that motor dysfunction and FMAR share common under-

AD biomarkers (both CSF and PiB PET imaging). The Knight ADRC

lying pathophysiology (i.e., neurodegeneration). While activity level

cohort is significant given the nature of the data collected, with detailed

is only one domain in the assessment of motor function, we did not

clinical and dementia assessments that ensure consistent phenotyp-

observe a strong association between FMAR and daily activity lev-

ing. Actigraphy was collected for 14 days, providing an excellent source

els. Motor function is multifaceted and likely only partially reflected

data for analyses, in combination with established FMAR analysis pro-

in FMAR. In addition, FMAR may involve the other physiological con-

tocols. When we assume irreversibility of AD pathology, having an

trol systems that interact with the motor control system.48 More work

assessed value for Δα greater than the 50th centile value in this cohort

is required to understand how FMAR reflects healthy motor function

was associated with more than 1-fold increased odds of being PiB+ at

beyond simply total activity levels.

the time of imaging, which was comparable to the odds of PiB+ from

Finally, there is increasing evidence that rest/activity patterns, a

being a APOE ε4 carrier versus a non-carrier (Table S1). The poten-

proxy for underlying circadian regulation (the body’s daily rhythm and

tial application of FMAR measures in screening people with a high

control of physiological processes), is an early sign of AD preceding

probability of AD pathology should be desirable because AD biomark-

the onset of cognitive symptoms.16,49,50 At the same time, our work

ers such as amyloid and tau are expensive or invasive to obtain. To

has shown that the maintenance of fractal activity patterns requires

improve upon its utility, future work should combine this unobtrusive

intact circadian regulation.33,51 Given that higher IV, a measure of

monitoring method in participants’ natural environment, with other

rest/activity pattern fragmentation, was also positively correlated

inexpensive/non-invasive clinical measures; this makes it more feasible

with AD pathology in the same cohort,16 it is not surprising that FMAR

to identify higher risk individuals at an earlier stage, who may then go

degradation trended toward a positive correlation with higher IV (Fig-

onto lumbar puncture or AD imaging.52–55

ure S1 in supporting information). However, the relationship between

We acknowledge some limitations of our study. The cohort was

FMAR and preclinical AD remained significant despite the inclusion

relatively homogeneous; therefore, we were unable to fully consider

of IV in our final model. We would argue these results for FMAR

race or ethnicity in our analyses. It is possible that changes in FMAR

show consistency with prior circadian links to AD. Taken together,

occurred during up to 3-year’s lag between actigraphy recording and

we believe FMAR better encompasses physiological processes rel-

AD biomarker measurement. However, assuming irreversibility of AD

evant to cognitive decline than age alone, individual measures of

pathology and the strength of association within the two separate

activity levels, rest/activity patterns, and even genetic predispo-

AD pathology measures, it seems probable that the time lag would

sition by revealing unique information in preclinical AD. Future

have biased our findings toward the null. It is also possible that the

studies determining the neural circuitry for FMAR may shed light on

observed relationships are caused by non-amyloid/tau pathologies in

the neuroanatomical/neuropathological changes underlying these

the aged brain. In particular, sleep disordered breathing is common and

findings.

can influence amyloid burden,56 but was not assessed in this cohort.
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The relationship between FMAR alterations and other types of dementia has also not yet been explored. Ultimately, external validation and
replication are needed with more male subjects, in undiagnosed participants with MCI, and accounting for comorbidities and medications
that may affect both motor activity patterns and AD pathology.
In summary, we found that FMAR degrades with preclinical AD
pathology, and that this effect was largely driven by female participants. The proposed FMAR measure is independent of age, APOE ε4
status, mean daily activity, and rest/activity patterns. These results
warrant further investigation to establish the potential of fractal
regulation as a passively obtained, non-cognitive and physiological
biomarker for AD. To improve the prediction/detection of AD dementia, future studies may combine FMAR with other imaging and/or
behavioral measures and use advanced techniques of machine learning
to extract the best features or biomarkers for AD risk.
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